BUDAPEST, HUNGARY--(Marketwire - July 01, 2009) - Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, is
pleased to present this Genetic Immunity release, based on a previously
announced agreement whereby Power of the Dream Ventures will issue
communications for Genetic Immunity on a going forward basis.
Genetic Immunity is pleased to announce completion of patient enrollment in
the Company's Phase II randomized, placebo-controlled trial designed to
investigate whether therapeutic immunization during highly active
antiretroviral therapy (HAART) induces elevations of HIV-specific T cell
precursors with high proliferative capacity (PHPC) in HIV-1-infected
individuals, and whether the quantity of PHPC correlates with the viral
load set point following analytical treatment interruption (ATI). This
second Phase II study is conducted at the IRCCS Policlinico S. Matteo in
Pavia, Italy with a total of sixteen patients.
"We are extremely pleased to have enrolled all patients in this, our second
Phase II trial aimed to prove the benefit of our immune amplification
therapy. We now have two trials underway, in addition to a Phase I/II trial
that is also nearing completion. I am confident this Italian trial, along
with the one conducted in Hamburg, Germany will show substantial benefit
for HIV infected patients. We look forward to receiving trial data once it
is completed early in 2010," commented Julianna Lisziewicz, CEO of Genetic
Subjects in the study are randomized to receive either DermaVir Patch (8
subjects per cohort) or DermaVir Patch Placebo (8 subjects per cohort)
every four weeks for three applications while receiving maximally
suppressive HAART. HAART will be discontinued at Week 9 for an ATI period
of 20 weeks.
Patients are on study for a total of 29 weeks (nine weeks of HAART followed
by 20 weeks of ATI). Each subject's DermaVir/Placebo application schedule
is administered over an 8-week period (Day 0, 28, and 56). HAART is
discontinued on Day 63 and is resumed on Day 203. Subsequently, individuals
who do not meet HAART restarting criteria can elect not to restart therapy.
After week 29 a safety and immunogenicity follow up evaluation is done
every 3 months for an additional year for all the participants.
For more information please visit the Company's official website at
About Genetic Immunity
Genetic Immunity is a US/Hungarian biopharmaceutical company establishing
leadership in Nanomedicines for immune amplification. Nanomedicine, an
offshoot of nanotechnology, refers to highly specific medical intervention
at the molecular scale for treating disease or repairing damaged tissues.
By leveraging its proprietary immune amplification platform technology, the
company aims to address new markets for infectious diseases, cancer and
allergies through the discovery, development and commercialization of
topically administered nanomedicines. These indications represent a
significant unmet medical need and the potential for alternative treatment
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company.
We identify and harness the unique technological prowess of Hungary's
high-tech industry, turning promising ideas and ready to market
products/technologies into global industry leaders. We focus on developing,
acquiring, licensing, or co-developing technologies that originate
exclusively in Hungary that are in prototype stage based on existing
patents; in prototype stage prior to patenting; existing products that
require expansion capital to commercialize; emerging science and
high-technology research projects that require help in patenting,
developing the product and marketing, University spin-off technologies, and
ideas from the very early stage that represent "disruptive technologies."
We primarily focus on providing enabling solutions in the fields of
environmental technologies, power generation and storage, software products
and services, biotechnology, medical devices and what we call 'disruptive
technologies.' For more information please visit our website at